A-674563 is a novel and potent Akt1 inhibitor with potential anticancer activity.

Perifosine (also known as KRX-0401) is a potent, orally bioavailable and synthetic antitumor alkylphospholipid (APL) which acts as an Akt inhibitor and a PI3K inhibitor with potential anticancer activity.

Triciribine (also known as API-2; NSC-154020; VQD-002), a cell-permeable tricyclic nucleoside molecule, is a potent DNA synthesis inhibitor with potential anticancer activity.

SPP-86 (SPP86) is a novel, cell-permeable and potent RET tyrosine kinase inhibitor (IC50 of 8 nM) with anticancer activities.

AT13148 is a novel, potent, orally bioavailable, ATP-competitive, multi-AGC kinase inhibitor with potential anticancer activity.

SC79 is a novel, potent, selective, cell-permeable, and brain-penetrable activator of Akt phosphorylation with the potential to be used to enhance Akt activity in various physiological and pathological conditions, e.g. to prevent progressive neuronal death in neurological diseases.

PF-04691502 is a novel, potent, ATP-competitive and selective dual inhibitor of PI3K (phosphatidylinositol 3 kinase) and mTOR (mammalian target of rapamycin) with potential anticancer activity.

GSK2110183 HCl, an analog of Afuresertib, is a potent, orally bioavailable and ATP-competitive Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively.

AT7867 Dihydrochloride is a novel, highly potent and ATP-competitive inhibitor of Akt1/Akt2/Akt3 and p70S6K/PKA with IC50s of 32 nM/17 nM/47 nM and 85 nM/20 nM in cell-free assays, respectively.

TIC10 Analogue (ONC201 isomer) is an analog/isomer of TIC10 and the ‘inactive form’ of TIC10.